Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Multicenter, Randomized, Open-Label Study Comparing the Efficacy, Safety, PK, and Tolerability of VH3810109, Administered Either Intravenously Or As A Subcutaneous Infusion With rHuPH20, in Combination With CAB LA to Standard of Care in Virologically Suppressed Adults Living With HIV

NCT05996471 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.

NCT NCT05996471
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05996471 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Multicenter, Randomized, Open-Label Study Comparing the Efficacy, Safety, PK, and Tolerability of VH3810109, Administered Either Intravenously Or As A Subcutaneous Infusion With rHuPH20, in Combination With CAB LA to Standard of Care in Virologically Suppressed Adults Living With HIV
Lead sponsor
ViiV Healthcare
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 17, 2023
Completion date
November 9, 2028
Enrollment
185 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections